Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with S / Sulfisoxazole
 
Sulfisoxazole
 

A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. [PubChem]
BrandsAccuzole
Alphazole
Amidoxal
Astrazolo
Azo Gantrisin
Azosulfizin
Bactesulf
Barazae
Chemouag
Cosoxazole
Dorsulfan
Dorsulfan Warthausen
Entusil
Entusul
G-Sox
Ganda
Gantrisin
Gantrisine
Gantrisona
Gantrosan
Isoxamin
J-Sul
Koro-Sulf
Neazolin
Neoxazol
Norilgan-S
Novazolo
Novosaxazole
Pancid
Renosulfan
Resoxol
Roxosul
Roxosul Tablets
Roxoxol
Saxosozine
Sk-Soxazole
Sodizole
Sosol
Soxamide
Soxazole
Soxisol
Soxitabs
Soxo
Soxomide
Stansin
Sulbio
Sulfagan
Sulfagen
Sulfalar
Sulfapolar
Sulfasan
Sulfasol
Sulfazin
Sulfisin
Sulfizin
Sulfizol
Sulfizole
Sulfoxol
Suloxsol
Sulphafuraz
Sulsoxin
Thiasin
Tl-Azole
Unisulf
Urisoxin
Uritrisin
Urogan
V-Sul
Vagilia
CategoriesAnti-Infective Agents
Anti-Infectives
Sulfonamides
ManufacturersHoffmann la roche inc
Mk laboratories inc
Alra laboratories inc
Parke davis div warner lambert co
Barr laboratories inc
Heather drug co inc
Impax laboratories inc
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Lannett co inc
Lederle laboratories div american cyanamid co
Pharmeral inc
Purepac pharmaceutical co
Roxane laboratories inc
Sandoz inc
Valeant pharmaceuticals international
Vitarine pharmaceuticals inc
Watson laboratories inc
West ward pharmaceutical corp
Solvay pharmaceuticals
Sola barnes hind
PackagersAmend
Barr Pharmaceuticals
Dispensing Solutions
Duramed
Major Pharmaceuticals
Mississippi State Dept Health
Pharmaceutics International Inc.
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Qualitest
United Research Laboratories Inc.
SynonymsSulfadimethylisoxazole
Sulfafurazol
Sulfafurazole
Sulfaisoxazole
Sulfasoxazole
Sulfisonazole
Sulfisoxasole
Sulfisoxazol
Sulfisoxazole Dialamine
Sulfisoxazole Diolamine
Sulfofurazole
Sulphafurazol
Sulphafurazole
Sulphafurazolum
Sulphaisoxazole
Sulphisoxazol
Sulphofurazole

indication

For the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.

pharmacology

Sulfisoxazole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

mechanism of action

Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.

toxicity

LD50=6800 mg/kg (Orally in mice)

route of elimination

The mean urinary excretion recovery following oral administration of sulfisoxazole is 97% within 48 hours, of which 52% is intact drug, with the remaining as the N4-acetylated metabolite. It is excreted in human milk.

drug interactions

Chlorpropamide: Sulfonamide/sulfonylurea: possible hypoglycemia

Methotrexate: The sulfamide increases the toxicity of methotrexate

Tamoxifen: Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed.

Tolbutamide: Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.

Torasemide: Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfisoxazole is initiated, discontinued or dose changed.

Trimethoprim: The strong CYP2C9 inhibitor, Sulfisoxazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfisoxazole is initiated, discontinued or dose changed.

Voriconazole: Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sulfisoxazole is initiated, discontinued or dose changed.

Warfarin: Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed.

Zafirlukast: Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfisoxazole is initiated, discontinued or dose changed.